Find policies, billing codes, payers, states, and providers
Prescription Medication and Illicit Drug Testing in the Outpatient Setting
Customize your policy alerts
Sign up for all Oscar Health policy alerts
Know when Oscar Health releases new policies or updates existing guidance.
Monitor payer policy activity
Policy governing outpatient clinical toxicology drug testing (presumptive and definitive) — when testing is covered, limitations, and reimbursement guidance for providers ordering urine, oral fluid, and select blood tests. Affects outpatient clinicians and laboratories submitting claims to Oscar Health.
No material clinical or coverage changes in this revision.
Coverage Criteria for Outpatient Drug Testing
inv-01: Presumptive Urine Screening
Presumptive drug screening using urine samples MEETS CRITERIA in any of the following situations:
Document rationale in chart.
Document maternal history or clinical concern.
Document transplant candidate history and purpose of testing.
Test when results will inform diagnosis or management.
Document clinical rationale.
Document indication in record.
Document clinical concern (e.g., unexplained seizures).
Frequency and randomization must be documented in the patient record.
Documentation of differential and clinical relevance required.
inv-02: Chronic opioid therapy monitoring frequency
Monitoring frequency for individuals on chronic opioid therapy (presumptive urine):
Risk level must be determined and documented in the medical record; random testing interval and drugs selected should be based on history, condition, and treatment.
inv-03: Definitive (confirmatory) testing
Confirmatory/definitive drug testing (up to seven drug classes) MEETS CRITERIA when laboratory-based definitive testing is specifically requested, the treating physician documents the rationale, and any of the following conditions are met:
Definitive testing must be ordered and justified by the treating physician and documented in the medical record.
inv-04: Not Covered - General
Other situations
Policy does not address state/federally mandated forensic testing, employment-related testing, or certain urgent/emergency testing contexts; proprietary tests and definitive panels >7 drug classes are excluded elsewhere.
inv-05: Clinically supported indications
Testing may be clinically useful in specific scenarios
Supported by cited studies showing benefit in these settings; routine testing for acute management broadly is of limited value.
inv-06: Modality and confirmation guidance
Test modality recommendations
Immunoassays have lower sensitivity/specificity (example: EIAs overall sensitivity 78.5% vs LC-MS/MS; opiate EIAs showed 21% false-negative rate); clinicians must understand assay limitations and consult laboratory personnel as needed.
inv-07: Recommended clinical testing indications and method preferences
Testing is recommended when clinical circumstances indicate benefit and should follow risk-stratified monitoring; definitive testing is preferred when results will alter management.
Sources include CDC, AAFP, AACC, FSMB; document rationale in the medical record.
Consensus guidance and CDC recommend confirmation when results will inform major decisions.
AACC and others emphasize knowing panel contents and limitations.
Document matrix rationale in the record.
inv-08: Risk-stratified monitoring frequency
Covered when testing aligns with risk-stratified monitoring recommended by cited guidelines
Sources: Washington State AMDG, Texas Pain Society, consensus panels; document risk assessment in the chart.
inv-09: Definitive confirmatory testing
Definitive testing recommended when any of the following apply
AACC and ASAM strongly recommend confirmatory testing in these scenarios; clinicians should obtain mass-spectrometry confirmation when results affect important decisions.
This policy does not address drug testing performed for state- or federally-mandated forensic purposes (for example, court-ordered or other legal/forensic examinations), for employment-related or commercial-driver licensing purposes, or as a component of care delivered in an urgent or emergency setting. Providers should follow applicable legal/regulatory requirements for mandated testing and not rely on this policy to determine requirements in those contexts.
Proprietary laboratory tests (vendor-specific assays) billed as either presumptive or definitive assays are not covered under this policy, and laboratory-based definitive panels that include more than seven drug classes DO NOT MEET CRITERIA. The policy also notes that related AMA definitive drug class codes are not reimbursed and requires that definitive testing be limited to the authorized panel size.
Routine, broad toxicology panels ordered for acute emergency department evaluation can be of limited clinical value and, in some settings, unnecessary. A multicenter retrospective analysis cited in the evidence section found no toxicity diagnoses from widespread acetaminophen/salicylate testing and characterized such routine screening as potentially "unnecessary and wasteful;" targeted testing based on clinical presentation is preferred.
The document cites evidence that routine pre-administration screening for acetaminophen or salicylates (for example, psychiatric premedication evaluations) may be unnecessary. The referenced multicenter VA study concluded that routine acetaminophen/salicylate testing in that context yielded no toxicity diagnoses and may represent low-value care.
The policy references expert guidance advising that quantitative urine definitive testing should not be used solely to assess patient dosage adherence or to guide prescribed dosing. Quantitative results may have roles in specific complex cases (variant metabolism, suspected spiking, or distinguishing multiple exposures), but should not be used as the only basis for changing dosing or declaring adherence.
The American College of Obstetricians and Gynecologists (ACOG) is cited noting that routine universal urine drug screening is controversial. ACOG recommends use of validated verbal screening tools (for example, 4Ps, NIDA Quick Screen, CRAFFT) and states that urine drug testing should be performed in compliance with state law and with patient consent rather than used as a universal, routine screen.
When definitive (confirmatory) testing is performed, the policy emphasizes that it should not be requested for the sole purpose of dosing decisions or adherence assessment alone. Documentation in the medical record must justify definitive testing, and clinicians should reserve quantitative definitive urine assays for situations where concentrations are needed to resolve complex analytic or clinical questions.
Procedure and billing codes listed in this policy are provided for reference only and are not, by their presence, an affirmation of coverage. Coding lists may not be exhaustive; providers should use the codes that most accurately reflect the services provided and consult the policy text for coverage rules.
The sections referenced for these items contain evidence citations and supporting references but do not themselves enumerate further explicit coverage exclusions beyond those stated elsewhere in the policy. Review of the full document and cited evidence is available in the references section.
Blanket orders or routine standing orders for all patients in a physician's practice are not reimbursed. The policy also disallows reimbursement for same-day duplicate testing of the same analyte from different specimen types (for example, both blood and urine) and limits multiple presumptive results reported for the same patient on the same date of service.
For most patients in acute clinical contexts, routine broad drug monitoring has limited utility according to the cited literature. The policy references systematic reviews and cohort studies that show variable benefit of broad, non-targeted drug testing for acute management and supports targeted testing in settings such as pain programs, addiction treatment, or where clinical presentation indicates.
The policy cites a multicenter retrospective study concluding that routine acetaminophen/salicylate screening before psychiatric medication administration produced no toxicity diagnoses, supporting the view that routine pre-administration screening in this context may be unnecessary.
Evidence summarized in the policy indicates that quantitative definitive urine testing does not demonstrably improve detection of clinically relevant outcomes in pain management compared with qualitative definitive testing for most monitoring purposes. The guidance therefore discourages relying on quantitative urine definitive testing solely to assess adherence or alter dosing.
Indications Where Testing Is Covered
Testing Frequency and Limitations
Billing Codes, Cutoffs, and Panel Sizes
| Any AMA definitive drug class codes | Specifically listed as not reimbursed |
| G0480 | Drug test(s), definitive; 1-7 drug classes; methods able to identify individual drugs and distinguish structural isomers; includes specimen validity testing, per day |
| G0481 | Drug test(s), definitive; continuation of definitive codes (see policy) |
| G0482 | Drug test(s), definitive; 8-14 drug classes |
| G0483 | Drug test(s), definitive; 15-21 drug classes |
| G0659 | Definitive drug test(s) performed without method- or drug-specific calibration or matrix-matched QC or without use of stable isotope internal standards; per specimen; any number |
| 80305 | Drug test(s), presumptive, any number of drug classes; direct optical read (eg, dipsticks, cups, cards, cartridges); includes sample validation, per date of service |
| 80306 | Drug test(s), presumptive; read by instrument-assisted direct optical observation (immunoassay); includes sample validation |
| 80307 | Drug test(s), presumptive; by instrument chemistry analyzers, chromatography, and/or mass spectrometry; includes sample validation |
| 80320 | Alcohol testing; includes sample validation when performed |
| 80321 | Alcohol biomarkers; 1 or 2 |
| 80307 | Drug test(s), presumptive; by instrument chemistry analyzers, chromatography, and/or mass spectrometry; includes sample validation |
| 80320 | Alcohols |
| 80321 | Alcohol biomarkers; 1 or 2 |
| 80322 | Alcohol biomarkers; 3 or more |
| 80323 | Alkaloids, not otherwise specified |
| 80324 | Amphetamines; 1 or 2 |
| 80325 | Amphetamines; 3 or 4 |
| 80326 | Amphetamines; 5 or more |
| 80327 | Anabolic steroids; 1 or 2 |
| 80328 | Anabolic steroids; 3 or more |
| 0051U | Prescription drug monitoring; 14 or more classes; definitive tandem mass spectrometry with chromatography; capillary blood; quantitative report including therapeutic and toxic ranges |
| 0054U | Prescription drug monitoring; 14 or more classes (paired proprietary listing) |
| 0082U | Prescription drug monitoring; evaluation of 65 common drugs by LC-MS/MS, urine; each drug reported detected or not detected |
| 0518U | Therapeutic drug monitoring; 80 or more psychoactive drugs or substances; LC-MS/MS, plasma; qualitative and quantitative |
| 0519U | Therapeutic drug monitoring; 90 or more pain and mental health drugs or substances; LC-MS/MS, plasma; qualitative and quantitative |
| 0520U | Therapeutic drug monitoring; 110 or more drugs/substances; LC-MS/MS, plasma; qualitative and quantitative |
| 0587U | Therapeutic drug monitoring/algorithmic analyses (SyncView®/SafeDrugs etc.); urine/saliva with risk score/reporting; proprietary platforms listed |
Provider Requirements, Documentation, and Billing Guidance
Prior authorization not specified in this excerpt
No explicit prior authorization requirement is stated in this portion of the policy document.
Prior authorization not specified
The document does not define any prior authorization process or requirement in the cited sections.
Baseline testing and risk‑based monitoring required
Providers should perform baseline urine drug testing prior to initiating controlled-substance therapy and follow risk-based periodic monitoring frequencies (at least annually for low-risk, more often for moderate/high risk).
- Baseline UDT recommended before starting opioids (AACC/consensus guidance).
- Ongoing monitoring frequency should reflect patient risk (e.g., annually for low-risk; two or more times/year for moderate-risk; three or more times/year for high-risk).
Authorization/justification for additional oral‑fluid testing per HHS
HHS guidance permits additional analyses on oral fluid specimens (including validity or biomarker testing) at the request of a Medical Review Officer and indicates additional testing may be performed when specimens exhibit abnormal characteristics.
- Practitioners must follow applicable authorization processes when requesting extra analyses in federal/workplace contexts.
- Additional testing may be performed for abnormal specimens (e.g., unusual odor/color, adulteration, or unidentified interfering substances).
Procedure codes for presumptive and definitive testing
Use the CPT/HCPCS codes listed in the policy for presumptive and definitive drug testing when billing; the document lists both presumptive (80305–80307 and related) and definitive (G0480–G0483, G0659) codes.
Supporting documentation required when billing proprietary U‑codes
When billing proprietary HCPCS (U-) codes, providers must have supporting documentation that links the billed U-code to the specific vendor/test and the clinical indication.
No prior authorization requirements specified here
No prior authorization requirements are specified in the cited policy chunks.
Step therapy not applicable; duplicate testing restricted
Step‑therapy sequencing is not applied; the policy restricts duplicate same‑day or multiple presumptive tests rather than imposing a step‑therapy requirement.
- Blanket or routine standing orders are not reimbursed.
- More than one presumptive test result per patient per date of service is not reimbursed.
Step therapy not specified
The policy does not specify step‑therapy rules in the referenced sections.
Obtain definitive confirmatory testing when POC/immunoassay results conflict with clinical expectations
If a point‑of‑care or immunoassay screening result is inconsistent with the patient's history or clinical presentation, obtain definitive confirmatory testing before making major management decisions.
- Confirm unexpected or clinically inconsistent immunoassay results with GC‑MS or LC‑MS/MS.
- Use confirmatory testing when results will inform decisions with major clinical or nonclinical implications.
ASIPP testing algorithm: baseline POC then risk‑stratified monitoring and confirmatory testing as needed
Follow the ASIPP algorithm: perform a baseline POC immunoassay at initiation; if results are appropriate, continue random POC monitoring in 1–3 months and then periodic testing (6–12 months); if results are inappropriate or unexplained, obtain confirmatory testing and repeat UDT at about one month or the next appointment.
- Baseline POC immunoassay recommended at initiation.
- Random POC monitoring at 1–3 months if baseline is appropriate; extend to 6–12 month intervals if continued appropriate.
- Inappropriate/unexplained results prompt confirmatory testing and repeat UDT ~1 month later.
UDT recommended for opioid risk assessment and ongoing monitoring
Guidelines recommend urine drug testing as part of risk assessment prior to initiating opioid therapy and for ongoing monitoring during opioid treatment.
- Perform baseline UDT before starting opioids and periodic monitoring thereafter.
- Use UDT results, alongside clinical judgment, to inform opioid therapy decisions and monitoring frequency.
Provider actions — see policy details
Refer to the policy text and cited sections for provider action requirements and context; no additional summary is provided in the inventory entry.
No step therapy rules in these excerpts
The cited chunks do not contain step‑therapy rules.
Record medical necessity and rationale for testing
The patient's medical record must document medical necessity for testing, including relevant history, physical exam, and pertinent diagnostic results.
- Documentation must fully support medical necessity for drug testing.
- Confirmatory/definitive testing should be supported by documented rationale in the medical record.
Document clinical rationale and intended use of test results
Documentation should justify the clinical intent for testing (e.g., baseline risk assessment, monitoring for compliance in pain management, psychiatric evaluation when stimulant exposure is suspected, or pre‑procedure evaluation).
- Clinical rationale must be documented to support targeted use of DOA testing.
- Routine or blanket testing without clear intent is discouraged and may not be reimbursed.
Document interpretation and justification for confirmatory testing
Document the clinical rationale, interpretation of test results, and the decision to use confirmatory testing when results are unexpected or will influence significant management decisions.
- Clinicians should be familiar with panels used and interpret results in clinical context.
- Confirmatory testing should be used when results will affect major clinical or nonclinical decisions.
Include specified documentation elements in the patient record
Ensure the medical record includes baseline assessment, a documented monitoring plan, an opioid agreement when applicable, PDMP review, and the rationale for testing frequency and any confirmatory tests.
- Include baseline assessment and monitoring plan in the record.
- Document PDMP review and opioid treatment agreement where relevant.
Obtain consent and request confirmatory mass‑spectrometry testing when indicated
Obtain patient consent where required by law and be aware of laboratory test characteristics; request confirmatory testing with mass spectrometry (GC/MS or LC‑MS/MS) when appropriate.
- ACOG advises UDT only with patient consent and knowledge of lab characteristics.
- Use GC‑MS or LC‑MS/MS confirmatory testing for unexpected or consequential results.
Support use of proprietary/LDT assays with documentation when billing U‑codes
When billing proprietary laboratory tests (U‑codes), maintain documentation that supports the specific vendor test (LDT) selection and the clinical indication for its use.
- Policy lists proprietary tests and manufacturers (e.g., UCompliDx, AssuranceRx, NextGen Precision, SyncView® series).
- Documentation should justify use of specific proprietary/LDT assays when billing corresponding U‑codes.
Evidence references present; no extra authorization documentation detailed
The policy includes an evidence/reference section but does not specify additional authorization documentation requirements beyond what is stated elsewhere.
Denial risk: duplicate same‑day or multiple presumptive testing
Same‑day testing of the same drug or metabolite from two different specimens (for example, both blood and urine) is not reimbursed, and more than one presumptive test result per patient per date of service is not reimbursed.
- It is not reasonable or necessary to perform POC qualitative testing and also order presumptive testing from a reference lab on the same specimen.
- Multiple presumptive immunoassay tests on the same specimen or same date of service are not reimbursed.
Denial risk if testing is not clinically indicated
Ordering testing without a clear clinical indication (for example, routine blanket screening for acute management) may be at risk for denial because evidence shows variable benefit in broad, routine DOA monitoring.
- Broad routine DOA monitoring for acute clinical management has limited evidence of benefit and may not be supported.
- Documented clinical indication increases likelihood of reimbursement.
Denial risk: not confirming unexpected results that affect major decisions
Failure to obtain confirmatory definitive testing when unexpected results will inform major clinical or nonclinical decisions risks inappropriate management; confirmatory testing is recommended in such scenarios.
- Use confirmatory GC‑MS or LC‑MS/MS when screening results are unexpected or will affect major decisions.
- Discussion with the patient before confirmatory testing may sometimes clarify findings and obviate immediate confirmatory testing.
Limitations/authorization for additional testing under HHS rules
Federal HHS rules allow additional testing of specimens with abnormal characteristics but may require authorization in certain workplace/federal contexts; follow applicable authorization processes.
- Additional testing may be performed for abnormal specimens (e.g., suspected adulteration) upon MRO request.
- Federal agency collection and testing rules specify circumstances (pre‑employment, random, reasonable suspicion, post‑accident, return‑to‑duty, follow‑up).
Government policy precedence may affect coverage/denials
If a government policy (e.g., LCD, NCD, or state Medicaid) conflicts with this Policy, the government policy will govern coverage determinations and may trigger denial or alternate handling.
Procedure codes listed for reference only
Procedure and HCPCS/CPT codes shown in the medical policy are provided for reference and may not be all‑inclusive; their presence does not by itself establish coverage.
No additional denial triggers specified here
No specific denial triggers are identified in the cited chunks beyond those already stated elsewhere in the policy.
Requirements for Ordering Tests
Treating physician must request and document definitive testing
Definitive testing must be specifically requested by the treating physician and the medical record must document the rationale for the definitive test and chosen frequency.
- Definitive testing requires a specific physician request with supporting rationale.
- Documentation of rationale in the patient's medical record is required for confirmatory/definitive testing.
Order tests for clear clinical objectives and confirm immunoassay findings when needed
Order tests based on clinical objectives and recognize that immunoassays are screening tools; confirmatory definitive testing is needed for positive or unexpected results that affect care.
- Be aware of immunoassay limitations (false positives/negatives) and consult package inserts or laboratory personnel as needed.
- Use confirmatory GC‑MS/LC‑MS/MS when accuracy is required for clinical decisions.
Request confirmatory definitive testing for unexpected or consequential results
Order confirmatory definitive testing when results are unexpected or will influence significant clinical or nonclinical decisions.
- Confirm discordant or unexplained presumptive results with laboratory definitive methods.
- Limit confirmatory testing to situations where results will reasonably affect patient management to reduce costs.
Order testing within a documented monitoring plan with PDMP review
Ensure testing is part of a documented monitoring plan that includes PDMP review and opioid treatment agreements where applicable; opioid treatment programs should follow program rules.
- Include PDMP review and opioid agreement documentation when ordering testing for opioid monitoring.
- OTPs should adhere to program‑specific requirements.
Obtain consent when required and recognize LDT/lab characteristics
Obtain informed consent where required by state law and be aware of laboratory test characteristics and LDT status when ordering tests.
- ACOG indicates UDT should be performed in compliance with state law and with patient consent.
- LDTs are CLIA‑regulated high‑complexity tests; providers should be aware when a test is an LDT.
No explicit ordering provider requirements specified here
The cited chunks do not impose explicit ordering provider type requirements; follow cited guidance and institutional policies for who may order tests.
Services Not Covered or Discouraged
Consistent with the coverage rules, proprietary vendor assays and definitive panels larger than seven drug classes are listed as not covered. The policy also states that same-day duplicate testing from separate specimens (for the same drug/metabolite) is not reimbursed, reinforcing limits on both proprietary and duplicative testing practices.
The policy identifies routine blanket toxicology screening of emergency department patients for acetaminophen or salicylates without a clinical indication as not reimbursed or low-value, citing a large multicenter retrospective study that found no toxicity diagnoses from such testing.
Routine, non-targeted screening such as widespread acetaminophen/salicylate testing before psychiatric medication administration is characterized in the evidence as unnecessary and wasteful; the policy therefore does not support blanket non-targeted screening without clinical indication.
The policy discourages use of quantitative urine definitive testing solely to assess patient medication adherence or to adjust prescribed dosage. It also clarifies that definitive testing must be supported by documentation and limited to panels of seven drug classes or fewer.
The policy indicates that routine universal urine screening without documented clinical indication is controversial and not endorsed as standard practice. ACOG guidance is cited recommending validated screening tools and informed consent rather than routine universal UDT, and the policy excludes mandated forensic and employment testing from its scope.
The document's referenced chunks do not provide an exhaustive list of additional tests that are categorically not covered beyond the explicit exclusions already stated; providers should consult the full policy and coding guidance for details.
Definitions and Test Methodology
Background and Evidence Context
Abuse of prescription and illicit drugs is common, and outpatient drug testing is used for monitoring adherence, diagnosing substance use disorders, and informing treatment. Urine is the most commonly used specimen because of its detection window and cost-effectiveness; testing modalities include presumptive immunoassays for screening and definitive chromatography/mass-spectrometry methods for confirmation and precise identification.
Document Governance and Revision History
Original documentation governance approved and published.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.